MeSH D016393 - b-cell lymphoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Johnson & Johnson | Ibrutinib | Imbruvica |  | 2014-10-21 | $3,095 M | Q4/23-Q3/24 |
| Roche | Rituximab | MabThera |  | 1998-06-02 |  |  |
| Polatuzumab vedotin | Polivy |  | 2020-01-16 | $888.584 M | Q4/22-Q3/23 | |
| Sandoz | Rituximab | Rixathon |  | 2017-06-15 |  |  |
| Rituximab | Riximyo |  | 2017-06-15 |  |  | |
| Pfizer | Rituximab | Ruxience |  | 2019-07-23 | $390 M | Y2023 |
| Zydus Therapeutics | Ibrutinib | Ibrutinib |  | 2021-03-31 |  |  |
| Bristol Myers Squibb | Lisocabtagene maraleucel | Breyanzi |  | 2022-04-04 | $585 M | Q4/23-Q3/24 |
| Biogen | Rituximab | Rituxan |  | 2002-02-19 |  |  |
| Celltrion | Rituximab | Blitzima |  | 2017-07-13 |  |  |
| Rituximab | Ritemvia |  | 2017-07-13 |  |  | |
| Rituximab | Rituzena (previously Tuxella) |  | 2017-07-13 |  |  | |
| Rituximab | Truxima |  | 2018-11-28 |  |  | |
| Genentech | Rituximab | Rituxan |  | 1997-11-26 |  |  |
| Rituximab, Hyaluronidase (human recombinant) | Rituxan Hycela |  | 2017-06-22 |  |  | |
| Pharmacyclics | Ibrutinib | Imbruvica | 2026-12-28 | 2013-11-13 | $312.698 M | Q2/14-Q1/15 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
79%74/94
Phase 2
21%23/111
Phase 3
20%7/35
Approved: 6Overall Success rate: 3%
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use